Aeglea BioTherapeutics In... (AGLE)
NASDAQ: AGLE
· Real-Time Price · USD
12.01
0.75 (6.66%)
At close: Nov 27, 2023, 10:00 PM
Aeglea BioTherapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -85.05M | -80.38M | -365.05M | -314.45M | -294.43M | -272.56M | -77.8M | -83.81M | -85.44M | -87.51M | -72.02M | -65.8M | -68.07M | -65.8M | -80.38M |
Depreciation & Amortization | -12.37M | -12.37M | 580K | 964K | 1.35M | 1.75M | 1.55M | 1.57M | 1.59M | 1.6M | 1.62M | 1.58M | 1.53M | 1.37M | 1.2M |
Stock-Based Compensation | 67.07M | 62.99M | 28.48M | 17.09M | 9.83M | 6.61M | 6.72M | 7.11M | 7.78M | 8.32M | 8.38M | 8.04M | 7.56M | 7.14M | 6.67M |
Other Working Capital | 24.59M | 17.68M | 18.65M | -12.11M | -2M | 3.83M | -1.54M | -2.86M | -8.17M | -6.26M | -140K | 768K | 7.24M | 6.76M | -306K |
Other Non-Cash Items | -19.19M | -10.52M | -19.28M | -20.05M | 8.6M | -5K | 243K | 280K | 438K | 663K | 619K | 638K | 557K | 313K | 398K |
Deferred Income Tax | -192.13M | -192.13M | 192.13M | 192.13M | 192.13M | 192.13M | 234K | 216K | 304K | 484K | 179K | 204K | 52K | -238K | -177K |
Change in Working Capital | 25.55M | 17.6M | 20.23M | -6.82M | -4.5M | 4.58M | -2.46M | -5.5M | -5.86M | -6.49M | 963K | 1.83M | 6.84M | 4.85M | -1.49M |
Operating Cash Flow | -221.2M | -214.8M | -142.91M | -131.12M | -87.01M | -67.48M | -71.52M | -80.14M | -81.27M | -83.2M | -60.45M | -53.72M | -51.58M | -52.12M | -73.61M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | -1K | -1K | -38K | -38K | -130K | -160K | -573K | -1.57M | -2.05M | -3.34M |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -771.51M | -812.7M | -326.08M | -291.02M | -117.13M | -11.75M | -36M | -39.5M | -48.25M | -67.25M | -112.33M | -133.08M | -150.83M | -147.08M | -149.25M |
Sales Maturities Of Investments | 432.02M | 360.64M | 138.92M | 78.88M | 39.5M | 63.25M | 85M | 96.55M | 100.96M | 109.33M | 106.33M | 111.03M | 148.74M | 145.47M | 139.53M |
Other Investing Acitivies | -18.51M | -3.51M | 18.51M | 18.51M | 18.51M | 3.51M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | -358M | -455.57M | -168.65M | -193.64M | -59.12M | 55.01M | 49M | 57.01M | 52.67M | 41.95M | -6.16M | -22.62M | -3.66M | -3.65M | -13.06M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 67.5M | 54.84M | 220.23M | 202.36M | 197.46M | 209.86M | 42.68M | 42.68M | 42.77M | 44.04M | 1.04M | 1.39M | 25.99M | 25.11M | 154.59M |
Financial Cash Flow | 226.7M | 214.04M | 210.6M | 197.83M | 197.46M | 209.86M | 42.68M | 42.68M | 42.77M | 44.04M | 1.04M | 1.39M | 25.99M | 25.11M | 154.59M |
Net Cash Flow | -196.58M | -300.43M | -100.31M | -126.6M | 51.38M | 197.4M | 20.09M | 19.44M | 14.02M | 2.66M | -65.61M | -74.96M | -29.22M | -30.6M | 67.98M |
Free Cash Flow | -221.2M | -214.8M | -142.91M | -131.12M | -87.01M | -67.49M | -71.52M | -80.18M | -81.31M | -83.33M | -60.61M | -54.29M | -53.15M | -54.16M | -76.95M |